SCHEMBL3752047

SCHEMBL3752047

CC1(C(=O)O)OC1C1=C(Cl)C(=O)c2ccccc2C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 7/20 0.43
DNMT1 P26358 1/20 0.42
DNMT3L Q9UJW3 1/20 0.42
DNMT3A Q9Y6K1 1/20 0.42
APEX1 P27695 2/20 0.40
HSP90AA1 P07900 3/20 0.40
HSP90AB1 P08238 2/20 0.40
AKT1 P31749 1/20 0.39
NSD2 O96028 3/20 0.39
G6PD P11413 1/20 0.39
CCR6 P51684 1/20 0.39
CDC25A P30304 3/20 0.38
MAPT P10636 3/20 0.37
KMT2A Q03164 3/20 0.37
HKDC1 Q2TB90 3/20 0.37
APAF1 O14727 1/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37
CASP3 P42574 1/20 0.37
RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13049666 1.00 IDO1 (0.43) IDO1DNMT1DNMT3LDNMT3AAPEX1
SCHEMBL13049436 0.82 IDO1 (0.41) IDO1HSP90AA1CCR6MAPTKMT2A
SCHEMBL5862723 0.71 KMT2A (0.40) MAPTKMT2APOLBMAPK1HTT
SCHEMBL5860484 0.71 KMT2A (0.40) MAPTKMT2APOLBMAPK1HTT
SCHEMBL329169 0.71 KMT2A (0.40) MAPTKMT2APOLBMAPK1HTT
SCHEMBL1280784 0.64 NPSR1 (0.56) KMT2ANPC1MAPK1HTTNPSR1
Dichlon SCHEMBL29360991 0.63 IDO1 (1.00) IDO1DNMT1DNMT3LDNMT3AHSP90AA1
Dichlon SCHEMBL45723 0.63 IDO1 (1.00) IDO1DNMT1DNMT3LDNMT3AHSP90AA1
Dichlon SCHEMBL9751236 0.63 IDO1 (1.00) IDO1DNMT1DNMT3LDNMT3AHSP90AA1
SCHEMBL11132699 0.63 KDM1A (0.42) MAPTKMT2APOLBMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2203161-B1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF UNIV INDIANA RES & TECH CORP (US) 2018-05-09 EP disclosed
US-9089605-B2 Quinone derivatives, pharmaceutical compositions, and uses thereof INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-07-28 US disclosed
US-9089605-B2 Quinone derivatives, pharmaceutical compositions, and uses thereof INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-07-28 US disclosed
US-9089605-B2 Quinone derivatives, pharmaceutical compositions, and uses thereof INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-07-28 US disclosed
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PURDUE RESEARCH FOUNDATION 2010-11-25 US disclosed
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PURDUE RESEARCH FOUNDATION 2010-11-25 US disclosed
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PURDUE RESEARCH FOUNDATION 2010-11-25 US disclosed
EP-2203161-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Indiana University Research and Technology Corporation (US) 2010-07-07 EP disclosed
WO-2009042544-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF APEX1, NQO1, REV1 IDO1 960/4885DNMT1 396/4885DNMT3L 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.